TARS - Tarsus Pharmaceuticals  - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

TARS is currently covered by 7 analysts with an average price target of $67.86. This is a potential upside of $20.5 (43.29%) from yesterday's end of day stock price of $47.36.

Tarsus Pharmaceuticals 's activity chart (see below) currently has 14 price targets and 39 ratings on display. The stock rating distribution of TARS is 89.66% BUY and 10.34% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 53.54% with an average time for these price targets to be met of 425.5 days.

Highest price target for TARS is $84, Lowest price target is $41, average price target is $62.

Most recent stock forecast was given by EDDIE HICKMAN from GUGGENHEIM on 02-May-2025. First documented stock forecast 10-Nov-2020.

Currently out of the existing stock ratings of TARS, 26 are a BUY (89.66%), 3 are a HOLD (10.34%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$84

$36.64 (77.36%)

$78

2 days ago
(02-May-2025)

3/5 (60%)

$36.64 (77.36%)

457

Buy

$73

$25.64 (54.14%)

$61

2 months 8 days ago
(26-Feb-2025)

7/10 (70%)

$30.44 (71.52%)

623

Buy

$60

$12.64 (26.69%)

$62

2 months 8 days ago
(26-Feb-2025)

2/5 (40%)

$17.44 (40.98%)

547

Buy

$72

$24.64 (52.03%)

$65

3 months 12 days ago
(22-Jan-2025)

2/8 (25%)

$23.89 (49.66%)

630

Hold

$41

$-6.36 (-13.43%)

$30

5 months 19 days ago
(15-Nov-2024)

2/3 (66.67%)

$-3.83 (-8.54%)

19

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is TARS (Tarsus Pharmaceuticals ) average time for price targets to be met?

On average it took 425.5 days on average for the stock forecasts to be realized with a an average price target met ratio 53.54

Which analyst has the current highest performing score on TARS (Tarsus Pharmaceuticals ) with a proven track record?

EDDIE HICKMAN

Which analyst has the current lower performing score on TARS (Tarsus Pharmaceuticals ) with a proven track record?

ANDREA TAN

Which analyst has the most public recommendations on TARS (Tarsus Pharmaceuticals )?

Eddie Hickman works at GUGGENHEIM and has 9 price targets and 7 ratings on TARS

Which analyst is the currently most bullish on TARS (Tarsus Pharmaceuticals )?

Dane Leone with highest potential upside - $51.89

Which analyst is the currently most reserved on TARS (Tarsus Pharmaceuticals )?

Andrea Tan with lowest potential downside - -$6.36

Tarsus Pharmaceuticals  in the News

Tarsus Pharmaceuticals Inc (TARS) Q1 2025 Earnings Call Highlights: Record Sales Surge and ...

Release Date: May 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Tarsus Pharmaceuticals Inc (NASDAQ:TARS) reported a significant year-over-year increase of 217% in sales for their product Exteny, generating over $78 million in the first quarter of 2025. The company has achieved broad...

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $1.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 7.25%. A quarter ago, it...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?